Orchard Therapeutics PLC
Ana Paula Luiz is a scientist with extensive experience in translational research and pain mechanisms. Currently serving as Scientist 1 at Orchard Therapeutics since September 2022, Ana Paula previously held the position of Associate Scientist in Discovery. At University College London, from May 2014 to August 2022, Ana Paula worked as a Research Associate focused on discovering new targets for acute and chronic pain treatment. Earlier roles included a Postdoctoral Fellowship in Science Without Borders, studying orofacial pain in mice, and a Postdoctoral Fellowship in Neuroscience investigating pain in a Parkinson's disease model. Educational qualifications include a PhD in Pharmacology, a Master’s in Neuroscience, and a Bachelor's in Pharmacy, all from Universidade Federal de Santa Catarina.
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.